Skip to main content

Constantino Sábado Álvarez

Institutions of which they are part

Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Constantino Sábado Álvarez

Institutions of which they are part

Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

La interacción entre el error innato de la inmunidad y los trastornos sanguíneos: desentrañando los defectos inmunitarios detrás de las enfermedades hematológicas comunes

IP: Pere Soler Palacín
Collaborators: Laura Batlle Masó, Maria Cristina Díaz de Heredia Rubio, Roger Colobran Oriol, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Miriam Gonzalez Amores, Janire Perurena Prieto, Andrea Martín Nalda, Lucas Moreno Martín-Retortillo, Jacques Gabriel Rivière
Funding agency: Instituto de Salud Carlos III
Funding: 179993.75
Reference: AC23_2/00033
Duration: 01/01/2024 - 31/12/2026

Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders

IP: Lucas Moreno Martín-Retortillo
Collaborators: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, María de los Ángeles Rodríguez Sánchez, Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders, Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Elisabet Megías Roda, Raquel Hladun Alvaro, Ariadna Boloix Amenós, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Júlia Sansa Girona, Gabriela Guillén Burrieza, Laura Alonso Garcia, Victoria Gutierrez Valle, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Elena Andretta, Claire Diot, Amira Idrizovic
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00638
Duration: 01/01/2022 - 30/06/2025

Desarrollo de nuevos fármacos basados en la inhibición de los co-receptores de la vía Hedgehog

IP: Josep Roma Castanyer
Collaborators: Desarrollo de nuevos fármacos basados en la inhibición de los co-receptores de la vía Hedgehog, Guillem Pons Barcons, Constantino Sábado Álvarez, Raquel Hladun Alvaro, Patricia Zarzosa Martinez
Funding agency: Instituto de Salud Carlos III
Funding: 122815
Reference: PI21/00640
Duration: 01/01/2022 - 31/12/2024

ESTRATEGIAS PARA MODULAR BRG1 COMO NUEVA TERAPIA PARA EL NEUROBLASTOMA

IP: Miguel Segura Ginard
Collaborators: ESTRATEGIAS PARA MODULAR BRG1 COMO NUEVA TERAPIA PARA EL NEUROBLASTOMA, Luís Gros Subias, Constantino Sábado Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 147620
Reference: PI17/00564
Duration: 01/01/2018 - 31/12/2020

Related news

"Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Related professionals

Josep Maria de Bergua Domingo

Josep Maria de Bergua Domingo

Predoctoral researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Olga Mendez Fernández

Olga Mendez Fernández

Main researcher
Biomedical Research in Urology
Read more
Anna Rey Pérez

Anna Rey Pérez

Predoctoral researcher
Neurotraumatology and Neurosurgery Research Unit (UNINN)
Read more
Olga Maisterra Santos

Olga Maisterra Santos

Main researcher
Neurovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.